Antiparkinsonian activity of adenosine A2A antagonists in experimental models

Adv Neurol. 1999:80:121-3.

Authors

Y Kuwana¹, S Shiozaki, T Kanda, M Kurokawa, K Koga, M Ochi, K Ikeda, H Kase, M J Jackson, L A Smith, R K Pearce, P G Jenner

Affiliation

¹ Pharmaceutical Research Institute, Kyowa Hakko Kogyo Company, Shizuoka, Japan.

PMID: 10410710

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Adenosine / analogs & derivatives
Adenosine / pharmacology
Antiparkinson Agents / therapeutic use*
Humans
Motor Activity / physiology
Parkinson Disease / drug therapy*
Phenethylamines / pharmacology
Purinergic P1 Receptor Antagonists*
Receptors, Purinergic P1 / drug effects
Receptors, Purinergic P1 / physiology
Xanthines / pharmacology

Substances

Antiparkinson Agents
Phenethylamines
Purinergic P1 Receptor Antagonists
Receptors, Purinergic P1
Xanthines
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine
KF 17837
Adenosine